Wróbel, Tomasz MTomasz MWróbelGrudzińska, AngelikaAngelikaGrudzińskaYakubu, JibiraJibiraYakubu0000-0001-7637-0559du Toit, TherinaTherinadu ToitSharma, KatyayaniKatyayaniSharma0000-0001-6818-0931Harrington, Jeremiah CJeremiah CHarringtonBjörkling, FredrikFredrikBjörklingJørgensen, Flemming SteenFlemming SteenJørgensenPandey, Amit VikramAmit VikramPandey0000-0001-8331-59022025-02-242025-02-242025-12https://boris-portal.unibe.ch/handle/20.500.12422/205003Prostate cancer (PCa) is one of the most prevalent malignancies affecting men worldwide, and androgen deprivation therapy (ADT) is a primary treatment approach. CYP17A1 inhibitors like abiraterone target the steroidogenic pathway to reduce androgen levels, but their clinical efficacy is limited by drug resistance and adverse effects. This study reports the synthesis and evaluation of novel CYP17A1 inhibitors derived from a previously identified hit compound. Several analogs were synthesised, including an unexpected di-cyano derivative, which demonstrated increased potency against CYP17A1 compared to abiraterone. Biological assays revealed that these compounds significantly inhibited CYP17A1 enzymatic activity and altered steroid biosynthesis. Among the newly synthesised inhibitors, compound 11 showed the highest potency (IC50 = 4 nM) and the related compound 14 presented a template for further development. A combined docking and molecular dynamics approach was used to identify the possible target binding modes of the compounds.enCYP17A1enzyme inhibitioninhibitorsprostate cancer600 - Technology::610 - Medicine & healtharticle10.48620/854713995083010.1080/14756366.2025.2463014